EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Diagnostic accuracy of the risk of malignancy index for adnexal masses in women over 35 years: a prospective cross-sectional study at a tertiary care centre in Punjab, India.

Dr Harpreet Kaur, Dr Pardeep Garg, Dr Harkiratjit Singh Bhullar, Dr Sarita Nibhoria

Student's Journal of Health Research Africa · 2026-09-30 · 7 (3) · 10

DOI: 10.51168/qqn8qs93 ↗
AbstractBibliografische Angaben

Abstract

Background: The risk of malignancy index (RMI) is widely used to decide which adnexal masses should be referred to a gynaecological oncologist, but few Indian studies report which tumours the index misses. This study estimated the accuracy of RMI at the conventional cut-off of 200 against histopathology, compared it with its individual components, and examined misclassified cases by histological type and menopausal status. Methodology: This prospective cross-sectional study enrolled 80 consecutive women aged over 35 years with an adnexal mass scheduled for surgery at a tertiary care teaching hospital in Punjab, India, from 23 April 2021 to 22 October 2022. RMI was calculated as U × M × CA-125, with the ultrasound score (U) and menopausal score (M) each 1 or 3. Histopathology was the reference standard. Results: Forty-seven of 80 masses (58.8%) were malignant. At a cut-off of 200, RMI had a sensitivity of 87.2% (95% CI 74.3–95.2), specificity of 87.9% (71.8–96.6), positive likelihood ratio 7.2 and negative likelihood ratio 0.15. The area under the ROC curve was 0.94 (0.88–0.99), higher than for CA-125 (0.84; P = .002), ultrasound score (0.85; P = .043) or menopausal status (0.83; P = .008) alone. Five of six false negatives were mucinous carcinomas: RMI detected 2 of 7 mucinous carcinomas against 39 of 40 other malignancies (P < .001). Specificity in postmenopausal women was 4 of 7. Conclusion: RMI at 200 performed as reported in other populations. A lower in-sample optimum near 160 rested on three mucinous carcinomas and is too unstable to replace 200. A low RMI should not overrule a malignant-appearing ultrasound, particularly when a mucinous tumour is possible. Recommendation: Multicentre studies that include women managed without surgery, document blinding, and compare RMI with International Ovarian Tumor Analysis (IOTA) models in the same patients are needed.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →